IP Library › Patent Application 13654632
Patent Application
App. No. 13/654,632

PHARMACEUTICAL COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/654,632
Abstract

The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.

Claims (12)

1 . A method of treating multiple sclerosis or clinically isolated syndrome (CIS) comprising the administration of a pharmaceutical composition comprising a glitazone and a fumaric acid monoalkyl ester and/or fumaric acid dialkyl ester to a patient having multiple sclerosis or clinically isolated syndrome.

2 . The method according to claim 1 , wherein the fumaric acid dialkyl ester is selected from dimethyl fumarate or diethyl fumarate and the fumaric acid monoalkyl ester is selected from monomethyl hydrogen fumarate or monoethyl hydrogen fumarate.

3 . The method according to claim 2 , wherein the fumaric acid dialkyl ester is dimethyl fumarate.

4 . The method according to claim 1 , wherein the glitazone is pioglitazone or rosiglitazone.

5 . The method according to claim 1 , wherein said composition comprises a fumaric acid dialkyl ester selected from dimethyl fumarate or diethyl fumarate, the glitazone is pioglitazone or rosiglitazone and said pharmaceutical composition is a solid oral dosage form.

6 . The method according to claim 5 , wherein said fumaric acid dialkyl ester is dimethyl fumarate.

7 . The method according to claim 1 , wherein said patient has multiple sclerosis.

8 . The method according to claim 1 , wherein said patient has clinically isolated syndrome.

9 - 15 . (canceled)

16 . The method according to claim 1 , wherein said pharmaceutical composition comprises a glitazone and a fumaric acid monoalkyl ester.

17 . The method according to claim 1 , wherein said pharmaceutical composition comprises a glitazone and a fumaric acid dialkyl ester.

18 . The method according to claim 1 , wherein said pharmaceutical composition comprises a glitazone, a fumaric acid monoalkyl ester and a fumaric acid dialkyl ester.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2012
From: KAHRS, BJOERN C.
To: ARES TRADING S.A.
Reel/Frame 029178/0981 →